Veracyte (VCYT) EPS (Weighted Average and Diluted) (2019 - 2025)
Veracyte (VCYT) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.5 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 733.33% to $0.5 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.82 through Dec 2025, up 173.33% year-over-year, with the annual reading at $0.82 for FY2025, 164.52% up from the prior year.
- EPS (Weighted Average and Diluted) hit $0.5 in Q4 2025 for Veracyte, up from $0.24 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.5 in Q4 2025 to a low of -$0.66 in Q1 2021.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.08 across 5 years, with a median of -$0.12 in 2023.
- Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 660.0% in 2023 and later soared 733.33% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.14 in 2021, then skyrocketed by 64.29% to -$0.05 in 2022, then crashed by 660.0% to -$0.38 in 2023, then skyrocketed by 115.79% to $0.06 in 2024, then skyrocketed by 733.33% to $0.5 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for VCYT at $0.5 in Q4 2025, $0.24 in Q3 2025, and -$0.01 in Q2 2025.